Abstract Details

Title Associations of the Neurological Institute of Athens Sleep-mediated Neuropsychological Battery to Biomarkers of Neurodegeneration

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 13-013

Objective

We examined whether the Neurological Institute of Athens (NIA) Sleep-Mediated Neuropsychological Battery (SM-NP) can predict neurodegenerative brain burden.

Background Sleep-mediated cognitive processes, especially episodic memory and executive function, are associated with brain neurodegeneration. Leveraging fast and easy sleep-mediated cognitive tests in clinic may lead to improved diagnosis, prognosis, and treatment response assessments.

Design/Methods

We recruited 45 older patients with either cognitive or sleep disorders and non-impaired controls (Age 66.5 ± 9.9; F:M 24:21) through the Sleep & Memory Center at the NIA as part of the MES-CoBraD Horizon2020 project. Participants underwent structured clinical examinations, within-day neuropsychological testing, actigraphy, polysomnography, pre- and post-sleep plasma analyses (p-tau217, total Tau, Aβ40, Aβ42, GFAP, NFL, insulin, cortisol), and the 12-minute-long SM-NP containing a 9-item learning task and a phonemic fluency task. We explored associations between pre- and post-sleep plasma biomarkers and SM-NP metrics through parametric correlations and partial correlations, and applied 5-fold linear discriminant analysis using SM-NP metrics to classify people into high vs. low likelihood of Alzheimer’s disease (AD) pathology using p-tau217 as the gold standard (<0.4 or >0.63 pg/mL). Multiple comparisons were addressed with Holm–Bonferroni correction.

Results Learning, recall, and recognition metrics were associated with pre- and post-sleep p-tau217 and GFAP (r = -0.53 - -0.69; p<0.0001), whereas only pre-sleep phonemic fluency was associated with pre-sleep p-tau217 (r=-0.54; p=0.0001), suggesting that executive difficulties worsen at night in neurodegeneration. The SM-NP classification accuracy was 80.5%, with episodic memory metrics having the highest loadings (-0.66 – -0.79), age somewhat lower (0.55), and sex and phonemic fluency the lowest (-0.13 – 0.09). Pre- to post-sleep p-tau217-based AD grouping changed in 14.3%, with morning values being larger.

Conclusions

The SM-NP is easy-to-administer and fast and is both correlated to and accurate in predicting neurodegeneration-associated plasma biomarkers. Furthermore, timing of blood collection modifies the sensitivity and specificity of plasma p-tau217.

Authors/Disclosures
Elissaios Karageorgiou, MD, PhD, FAAN (Neurological Institute of Athens) PRESENTER	Dr. Karageorgiou has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrtelle. The institution of Dr. Karageorgiou has received research support from European Union. The institution of Dr. Karageorgiou has received research support from Alzheimer's Association.
Nikolaos Andronas, MD (Neurological Institute of Athens)	The institution of Dr. Andronas has received research support from European Union THALES & ARISTEIA research programs . The institution of Dr. Andronas has received research support from European Union Horizon 2020.
Konstantina Sykara (Neurological Institute of Athens)	Konstantina Sykara has nothing to disclose.
Athanasia Alexoudi, MD	Dr. Alexoudi has nothing to disclose.
ZOI DEVENOPOULOU, midwife	Miss DEVENOPOULOU has nothing to disclose.
Margarita Maimani (Neurological Institute of Athens)	Margarita Maimani has nothing to disclose.
lei zhang, PhD	Dr. zhang has nothing to disclose.
Luiz Eduardo Mateus Brandao (Uppsala University)	The institution of Luiz Eduardo Mateus Brandao has received research support from FORTE - Swedish Research Council for Health, Working Life and Welfare. The institution of Luiz Eduardo Mateus Brandao has received research support from Fredrik and Ingrid Thuring's Foundation . The institution of Luiz Eduardo Mateus Brandao has received research support from Lars Hierta Minne's Foundation .
Jonathan Cedernaes	Jonathan Cedernaes has received personal compensation in the range of $500-$4,999 for serving as a Speaker fee with Takeda Pharma AB. Jonathan Cedernaes has received personal compensation in the range of $500-$4,999 for serving as a Speaker fee with Stolpe Publishing house.
Klimentini Karageorgiou, DO (General Hospital of Athens)	No disclosure on file